Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternate Day Buprenorphine Administration Phase XII
NCT00000235Phase 2Completed
- Sponsor
- National Institute on Drug Abuse
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of buprenorphine in opioid use disorder (OUD) (2 arms), sponsored by National Institute on Drug Abuse. Primary endpoints: Drug use, Opioid withdrawal and 2 more. Status: completed.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT00000235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000235.